| Autor: |
Beltran Gonzalez JL; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., González Gámez M; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Mendoza Enciso EA; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Esparza Maldonado RJ; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Hernández Palacios D; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Dueñas Campos S; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Robles IO; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Macías Guzmán MJ; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., García Díaz AL; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Gutiérrez Peña CM; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Martinez Medina L; Pediatrics Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Monroy Colin VA; Pediatrics Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico., Arreola Guerra JM; Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico. |
| Jazyk: |
angličtina |
| Zdroj: |
Infectious disease reports [Infect Dis Rep] 2022 Mar 03; Vol. 14 (2), pp. 160-168. Date of Electronic Publication: 2022 Mar 03. |
| DOI: |
10.3390/idr14020020 |
| Abstrakt: |
During the first year of the COVID-19 pandemic, unauthorized drugs were widely used. Ivermectin and hydroxychloroquine are drugs that inhibit viral replication in vitro and that have been used in several medical centers. This clinical trial analyzes their efficacy in hospitalized patients with moderate COVID-19. Methods: This a controlled, clinical, randomized, double-blind trial that included hospitalized patients with COVID-19-induced pneumonia, without severe respiratory failure. Patients were randomized to one of three groups: Group 1-hydroxychloroquine, 400 mg every 12 h on the first day and, subsequently, 200 mg every 12 h for 4 days; Group 2-ivermectin, 12 mg or 18 mg, according to patient weight; and Group 3-placebo. At inclusion, blood samples for arterial blood gases and biochemical markers were obtained. The primary outcome was established as the length of stay due to patient improvement and the rate of respiratory deterioration or death. Results: During the month of August 2020, the admission of patients requiring hospitalization mostly encompassed cases with severe respiratory failure, so we ended the recruitment process and analyzed the data that was available at the time. One hundred and six (106) patients with an average age of 53 yrs (±16.9) were included, with a greater proportion of males (n = 66, 62.2%). Seventy-two percent (72%) (n = 76) had an associated comorbidity. Ninety percent (90%) of patients were discharged due to improvement (n = 96). The average duration of hospitalization was 6 days (IQR, 3-10). No difference in hospitalization duration was found between the treatment groups (Group1: 7 vs. Group 2: 6 vs. Group 3: 5, p = 0.43) nor in respiratory deterioration or death (Group 1: 18% vs. Group 2: 22.2% vs. Group 3: 24.3%, p = 0.83). Conclusions: In non-critical hospitalized patients with COVID-19 pneumonia, neither ivermectin nor hydroxychloroquine decreases the number of in-hospital days, respiratory deterioration, or deaths. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
